InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Normocin™ - Antimicrobial Reagent | Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 ... | 2023 | Antivir. Res. | Corona A. et al. | DOI: 10.1016/j.antiviral.2023.105554 |
| HEK-Blue™ Null1 Cells | Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 ... | 2023 | Antivir. Res. | Corona A. et al. | DOI: 10.1016/j.antiviral.2023.105554 |
| Zeocin® | Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 ... | 2023 | Antivir. Res. | Corona A. et al. | DOI: 10.1016/j.antiviral.2023.105554 |
| HEK-Blue™ Detection | Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 ... | 2023 | Antivir. Res. | Corona A. et al. | DOI: 10.1016/j.antiviral.2023.105554 |
| Human TLR3 Reporter HEK293 Cells (NF-κB) | Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 ... | 2023 | Antivir. Res. | Corona A. et al. | DOI: 10.1016/j.antiviral.2023.105554 |
| Blasticidin | Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 ... | 2023 | Antivir. Res. | Corona A. et al. | DOI: 10.1016/j.antiviral.2023.105554 |
| Human TLR4 Reporter HEK293 Cells (NF-κB) | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| TLR2 signaling inhibitor | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| QUANTI-Blue™ | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| Human TLR2 and TLR1 Reporter HEK293 Cells (NF-κB) | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| FSL-1 | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| FLA-BS (Standard or Ultrapure) | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| LPS-EB (LPS from E. coli O111:B4) | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| Human TLR2 Reporter HEK293 Cells (NF-κB) | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| HKLM | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| Human TLR2 and TLR6 Reporter HEK293 Cells (NF-κB) | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| CU-T12-9 | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| Human TLR5 Reporter HEK293 Cells (NF-κB) | BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer. | 2023 | Inflamm Res. | Śmiałek-Bartyzel J. et al. | DOI: 10.1007/s00011-023-01721-3 |
| LPS-EB (LPS from E. coli O111:B4) | Chimeric Peptidomimetic Antibiotic Efficiently Neutralizes Lipopolysaccharide... | 2023 | ACS Infect Dis. | Javed A. et al. | DOI: 10.1021/acsinfecdis.2c00518 |
| LPS-EK (LPS from E. coli K12) | Chimeric Peptidomimetic Antibiotic Efficiently Neutralizes Lipopolysaccharide... | 2023 | ACS Infect Dis. | Javed A. et al. | DOI: 10.1021/acsinfecdis.2c00518 |